Reuters logo
BRIEF-CSL's unit says ‍new phase III study shows significantly greater efficacy in children 6-24 months who receive AQIV​
September 11, 2017 / 3:45 PM / a month ago

BRIEF-CSL's unit says ‍new phase III study shows significantly greater efficacy in children 6-24 months who receive AQIV​

Sept 11 (Reuters) - CSL Ltd:

* ‍New phase III study shows significantly greater efficacy in children 6-24 months who receive adjuvanted influenza vaccine (AQIV)​

* ‍AQIV demonstrates additional clinical benefit over non-adjuvanted QIV influenza vaccine in children aged 6 to less than 24 months​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below